- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UC…Endpoints · 2mo ago↗ source
- Bristol Myers’ pivotal year; Should AI be swinging bigger?; and moreWelcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-brea…Endpoints · 2mo ago↗ source
- Moderna in talks with FDA over Phase 4 Covid vaccine dataModerna said it's working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after FDA leaders narrowed the label for the produ…